| Methods | n = 30, 1 centre Allocation concealment: not described Baseline similarity: age Blinding: caregivers not blinded (no placebo) Cointerventions: not described Withdrawals: none Losses to follow‐up: none |
|
| Participants | Inclusions: metastatic cancer; diffuse CXR infiltrates, rapid fall in PaO2, and absence of congestive heart failure | |
| Interventions | IV pentoxyfylline 100 mg twice daily for 7 days, then 400 mg orally three times daily; or no pentoxifylline | |
| Outcomes | 1 month mortality: 10/15 (pentoxifylline group) and 15/15 (control group); RR 0.67 (95% CI 0.47 to 0.95) Adverse events leading to discontinuation of therapy: none |
|
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.